Home > Neurology > Pyrotinib plus capecitabine promising for HER2-positive breast cancer brain metastases

Pyrotinib plus capecitabine promising for HER2-positive breast cancer brain metastases


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The Lancet Oncology
Reuters Health - 11/02/2022 - In women with HER2 (ERBB2)-positive breast cancer brain metastases, combination therapy with pyrotinib and capecitabine elicited an intracranial response in a phase 2 trial. The combination "can be a reasonable option for HER2-positive breast cancer brain metastasis with reasonable response and minimal side effects," study coauthor Dr. Kazuaki Takabe of Roswell Park Comprehensive Cancer Center in Buffalo, New York, told Reuters Health by email. However, he said, "This study (PERMEATE) was conducted exclusively in Chinese institutions; thus, patients were homogenously far-east Asians. The study design was single arm without a control group. The response assessment was done by each investigator." "The next step is to conduct a randomized control trial enrolling multiple ethnic background patients with a central review of response assessment," he said. "Given the tolerable adverse events, a trial using multiple pan-HER receptor tyro...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on